Ipamorelin Australia

Ipamorelin Australia. Ipamorelin is a synthetic pentapeptide studied in laboratory research as a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) — the cleanest standalone GHRP-class research peptide. The Elite AU Peptides Ipamorelin is independently HPLC-tested by Janoshik; the certificate of analysis is published on this page and in the lab-reports library, with the measured number and an independently verifiable Janoshik key.

Available in 5 mg and 10 mg lyophilised vials, AU-domestic, AUD pricing. Every batch is held until the independent HPLC report comes back within our acceptance threshold; nothing is listed without a certificate on file. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption, not a therapeutic good, not TGA-approved.

Ipamorelin (CAS 170851-70-4; molecular formula C38H49N9O5, average molecular weight ≈ 712 g/mol; sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide referenced as a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) — the "GHRP" class of research peptides, alongside GHRP-2, GHRP-6 and Hexarelin.

Ipamorelin was introduced and characterised by Raun and colleagues (European Journal of Endocrinology, 1998) as the first selective growth-hormone secretagogue: in their research models it released growth hormone with a potency comparable to GHRH while, unlike older GHRPs, not significantly cross-activating the ACTH/cortisol axis — the selectivity profile that makes it the "cleanest" standalone GHRP in the literature.

The receptor it agonises — the G-protein-coupled growth-hormone-secretagogue receptor (GHS-R1a) — was cloned and identified by Howard and colleagues (Science, 1996), the molecular basis for GHRP-class receptor research.

In research models, Ipamorelin is most frequently studied alongside a GHRH-analogue (e.g. CJC-1295 no DAC) — the standard research pairing combines a GHRH and a GHRP because the two receptor classes act on distinct convergence points of the same somatotrophic-axis research model. See the CJC-1295 (no DAC) + Ipamorelin research blend product page for the co-lyophilised research-stack variant, and the CJC-1295 (no DAC) standalone product page for the GHRH partner.

The information provided here is a research-reference summary only. Elite AU Peptides makes no medical, therapeutic, performance, or human-use claim about this product. Ipamorelin is not TGA-approved, is not a therapeutic good, and is supplied strictly for in-vitro and laboratory research use only. Researchers should consult the primary peer-reviewed literature for receptor-binding affinities, pharmacokinetic data, and protocol-specific reference values.

Reconstitute the lyophilised Ipamorelin vial with bacteriostatic water for laboratory handling. Add the diluent slowly down the vial wall and swirl gently rather than shaking. The required volume depends on the protocol’s downstream assay requirements — a 5 mg vial reconstituted in 2.5 mL of bacteriostatic water yields a 2 mg/mL working stock. Adjust per protocol.

Store the lyophilised powder at −20°C, desiccated and protected from light; once reconstituted, store refrigerated at 2–8°C and use within the documented research window, or aliquot and freeze to avoid repeated freeze-thaw cycles. Tamper-evident packaging; the batch label is the canonical reference for the certificate of analysis published in the lab-reports library.

Shop bacteriostatic water

Australia only. Free shipping over $100. Orders placed before 12pm AEST are dispatched the same business day from Australia.

30-day returns on unused product in original packaging, with prior approval.